Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety, and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients with Cirrhosis and Associated Hyperammonemia with an Episode of Hepatic Encephalopathy (STOP-HE)
The purpose of this study is to determine whether ornithine phenylacetate can speed recovery from an acute hepatic encephalopathy episode requiring hospitalization in cirrhotic patients.
Trial Website: https://clinicaltrials.gov/show/NCT01966419
Are you Eligible? (Inclusion Criteria)
Inclusion Criteria:
- Hospitalized with an acute episode of hepatic encephalopathy as complication of cirrhosis
- Elevated venous ammonia
Exclusion Criteria:
- Renal failure with serum creatinine > 3 mg/dL or need for dialysis
- Molecular Adsorbent Recirculation System utilized
- Pregnancy or breastfeeding
Specialty Area(s)
Liver